Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2021 | Emerging agents in HR+ breast cancer

Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, touches on emerging agents evaluated in patients with hormone receptor-positive (HR+) breast cancer, including AKT inhibitors and antibody-drug conjugates in the metastatic space, as well as oral selective estrogen receptor degraders (SERDs) in the early disease space. This interview took place during the 17th St. Gallen International Breast Cancer Conference.

Disclosures

Institutional Research Funds: AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Cyclacel, Sanofi, Odonate, Seattle Genetics
Honoraria: AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Odonate, Seattle Genetics, Daiichi Sankyo, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Kyowa Kirin Pharmaceuticals, CytomX, Certara, Mersana Therapeutics